AVALO THERAPEUTICS INC (AVTX:NASDAQ)
$19.21 -0.74 (-3.7093%)
Analysed AVALO THERAPEUTICS INC (AVTX:NASDAQ) News Sources
This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A Breakout
06-05-2026
yahoo.com
Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
13-05-2026
yahoo.com
Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
22-05-2026
yahoo.com
Sector Update: Healthcare Stocks Softer Late Afternoon
12-06-2026
yahoo.com
Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody
16-06-2026
yahoo.com
Avalo Therapeutics Appoints Ron Philip to Board of Directors
23-06-2026
yahoo.com
Why Avalo Therapeutics, Inc. (AVTX) Is Among the Best Low Priced Stocks to Get Rich in 2026
23-06-2026
yahoo.com
Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes
26-06-2026
yahoo.com
Avalo Therapeutics (AVTX) Is Up 12.9% After Broad Russell Index Additions - What's Changed
30-06-2026
yahoo.com
Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum
07-07-2026
yahoo.com
What is the current price of AVALO THERAPEUTICS INC (AVTX:NASDAQ)?
The current price of AVALO THERAPEUTICS INC (AVTX:NASDAQ) is $19.21.
AVALO THERAPEUTICS INC (AVTX:NASDAQ) absolute price change since previous trading day?
The absolute price change of AVALO THERAPEUTICS INC (AVTX:NASDAQ) since the previous trading day is $-0.74.
AVALO THERAPEUTICS INC (AVTX:NASDAQ) percentage price change since previous trading day?
The percentage price change of AVALO THERAPEUTICS INC (AVTX:NASDAQ) since the previous trading day is -3.7093%.
What is the most recent average sentiment score for AVALO THERAPEUTICS INC (AVTX:NASDAQ)?
The most recent average sentiment score for AVALO THERAPEUTICS INC (AVTX:NASDAQ) is 85 out of 100.
What is the most recent average sentiment for AVALO THERAPEUTICS INC (AVTX:NASDAQ)?
The most recent sentiment for AVALO THERAPEUTICS INC (AVTX:NASDAQ) is .
SEC-8K** Filing Available For AVALO THERAPEUTICS INC (AVTX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.